» Articles » PMID: 34502419

Follistatin-Like-1 (FSTL1) Is a Fibroblast-Derived Growth Factor That Contributes to Progression of Chronic Kidney Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Sep 10
PMID 34502419
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Our understanding of the mechanisms responsible for the progression of chronic kidney disease (CKD) is incomplete. Microarray analysis of kidneys at 4 and 7 weeks of age in mice, a model of progressive nephropathy characterized by proteinuria, interstitial fibrosis, and inflammation, revealed that Follistatin-like-1 () was one of only four genes significantly overexpressed at 4 weeks of age. mRNA levels for the receptors, and , increased in both mice and mice subjected to unilateral ureteral obstruction (UUO). RNAscope (Advanced Cell Diagnostics, Newark CA, USA) localized to interstitial cells, and in silico analysis of single cell transcriptomic data from human kidneys showed confined to interstitial fibroblasts/myofibroblasts. In vitro, FSTL1 activated AP1 and NFκB, increased collagen I (COL1A1) and interleukin-6 (IL6) expression, and induced apoptosis in cultured kidney cells. expression in the NEPTUNE cohort of humans with focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and IgA nephropathy (IgAN) was positively associated with age, eGFR, and proteinuria by multiple linear regression, as well as with interstitial fibrosis and tubular atrophy. Clinical disease progression, defined as dialysis or a 40 percent reduction in eGFR, was greater in patients with high baseline mRNA levels. is a fibroblast-derived cytokine linked to the progression of experimental and clinical CKD.

Citing Articles

Renal tubular epithelial-derived follistatin-like 1 protects against UUO-induced renal fibrosis in mice via inhibiting NF-κB-mediated epithelial inflammation.

Niu Z, Guo J, Liu X, Chen M, Jin Y, Yao M Theranostics. 2025; 15(6):2413-2427.

PMID: 39990230 PMC: 11840719. DOI: 10.7150/thno.100969.


FSTL1 aggravates high glucose-induced oxidative stress and transdifferentiation in HK-2 cells.

Zhang B, Geng H, Zhao K, Omorou M, Liu S, Ye Z Sci Rep. 2025; 15(1):434.

PMID: 39748077 PMC: 11696259. DOI: 10.1038/s41598-024-84462-5.


Identification and validation of immune and cuproptosis - related genes for diabetic nephropathy by WGCNA and machine learning.

Chen Y, Liao L, Wang B, Wu Z Front Immunol. 2024; 15:1332279.

PMID: 38390317 PMC: 10881670. DOI: 10.3389/fimmu.2024.1332279.


Reconstructing growth and dynamic trajectories from single-cell transcriptomics data.

Sha Y, Qiu Y, Zhou P, Nie Q Nat Mach Intell. 2024; 6(1):25-39.

PMID: 38274364 PMC: 10805654. DOI: 10.1038/s42256-023-00763-w.


BMSCs alleviate liver cirrhosis by regulating Fstl1/Wnt/β-Catenin signaling pathway.

Zhangdi H, Geng X, Li N, Xu R, Hu Y, Liu J Heliyon. 2023; 9(11):e21010.

PMID: 37920508 PMC: 10618771. DOI: 10.1016/j.heliyon.2023.e21010.


References
1.
Ammar S, Kanoun H, Kammoun K, Domingo-Gallego A, Ruiz P, Lorente-Grandoso L . Next-generation sequencing in patients with familial FSGS: first report of collagen gene mutations in Tunisian patients. J Hum Genet. 2021; 66(8):795-803. DOI: 10.1038/s10038-021-00912-2. View

2.
Sundaram G, Common J, Gopal F, Srikanta S, Lakshman K, Lunny D . 'See-saw' expression of microRNA-198 and FSTL1 from a single transcript in wound healing. Nature. 2013; 495(7439):103-6. DOI: 10.1038/nature11890. View

3.
Prakoura N, Chatziantoniou C . Periostin and Discoidin Domain Receptor 1: New Biomarkers or Targets for Therapy of Renal Disease. Front Med (Lausanne). 2017; 4:52. PMC: 5422471. DOI: 10.3389/fmed.2017.00052. View

4.
Morrissey J, Guo G, McCracken R, Tolley T, Klahr S . Induction of CD14 in tubular epithelial cells during kidney disease. J Am Soc Nephrol. 2000; 11(9):1681-1690. DOI: 10.1681/ASN.V1191681. View

5.
Dong Y, Geng Y, Li L, Li X, Yan X, Fang Y . Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice. J Exp Med. 2015; 212(2):235-52. PMC: 4322044. DOI: 10.1084/jem.20121878. View